Mesenchymal stem cells derived from pluripotent stem cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1182368 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Pluripotent stem cells (PSCs), known for their unlimited ability to self-renew and differentiate into all three germ layers, have emerged as a promising cell source for regenerative therapies aimed at treating various diseases and injuries. However, the direct application of pluripotent stem cells brings many problems, including malignant teratoma formation and undirected differentiation. Pluripotent stem cell-derived mesenchymal stem cells may solve these problems. At the same time, pluripotent stem cell-derived mesenchymal stem cells can also solve the problems of adult mesenchymal stem cells, such as limited source, donor site trauma and strong heterogeneity. In this study, pluripotent stem cells were used as the starting point for differentiation into mesenchymal stem cells. Bulk RNA-seq was performed on differentiated cells.
2025-07-02 | GSE281140 | GEO
Project description:mouse embryonic fibroblasts, embryonic stem cells, and induced pluripotent stem cells were compared via metabolomic analysis
2018-08-02 | MSV000082680 | GNPS
Project description:Comparison of whole genome gene expression profiles of human testis derived ES-like cells with pluripotent stem cells (human embryonic stem cell lines), adult human bone marrow derived mesenchymal stem cells and human dermal fibroblasts.
2011-11-02 | GSE27203 | GEO
Project description:Mesenchymal Stem/Stromal Cells (MSC) obtained from Pluripotent Stem Cells (PSC) constitute an interesting alternative to classical MSC in regenerative medicine. Amongst one of their many mechanism of action, MSC extracellular vesicles (EVs) raise as a suitable substitution of MSC in future cell-free based therapeutics approaches. EVs, unlike cells, do not elicit acute immune rejection and can be produced in large quantities and stored ready to use, until needed. Though therapeutic potential of MSC-EVs had already been proved, thorough characterization of them is still scarce. In this work we performed a label-free Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) proteomic approach to identify the most abundant proteins in EVs secreted from MSC derived from PSC (PD-MSC) and from their parental iPSC. Next, we compared both datasets finding that while iPSC EVs enclose proteins that modulates RNA and miRNA stability and protein sorting, PD-MSC EVs are rich in proteins that organize extracellular matrix, regulate locomotion and influence cell-substrate adhesion. Moreover, when compared to their respective cells, iPSC and iPSC EVs share a greater proportion of proteins while PD-MSC proteome seems to be more specific. Correlation and Principal Component Analysis consistently aggregate iPSC and iPSC EVs but segregate PD-MSC and their EVs. Altogether these findings suggest that during differentiation, PD-MSC EVs acquire a more specific set of proteins than their parental iPSC�s EVs have and that, arguably, this might confer them their therapeutic properties.
2018-01-13 | MSV000081933 | MassIVE
Project description:Human induced-Pluripotent Stem Cells-derived Preepicardial Cells
| PRJNA625000 | ENA
Project description:Comparison of gene expression profiles of canine induced pluripotent stem cells (iPSC) and iPS derived mesenchymal stem cells (iMSC) by microarray Mesenchymal stem cells (MSCs) exhibit broad immune modulatory activity in vivo and can suppress T cell and dendritic cell activation in vitro. Currently, most MSC for clinical usage are derived from adipose or bone marrow tissues from younger donors, in part due to ease of procurement and to the superior immune modulatory activity of young MSC. However, use of MSC from multiple unrelated donors makes it difficult to standardize MSC cellular products with uniform immune modulatory properties. One solution to this problem is the use of MSC derived from induced pluripotent stem cells (iPSC), as iPSC-derived MSC have nearly unlimited proliferative potential and exhibit in vitro phenotypic stability. Given the value of dogs as a spontaneous disease model for pre-clinical evaluation of stem cell therapeutics, we investigated the functional properties of canine iPSC-derived MSC (iMSC), including their immune modulatory properties and their potential for teratoma formation. We found that canine iMSC downregulated expression of pluripotency genes and appeared morphologically similar to conventional MSC. Importantly, iMSC retained a stable phenotype even after multiple passages, did not form teratomas when inoculated in immune deficient mice, and did not induce tumor formation in purpose-bred dogs following systemic injection. The immune potency of iMSC was similar to that of adipose and bone-marrow derived MSC with respect to suppression of T cell and DC activation. We concluded therefore that iMSC were phenotypically stable, immunologically potent, and safe with respect to tumor formation, and represented an important new source of cells for therapeutic modulation of inflammatory disorders.
2017-01-26 | GSE94081 | GEO
Project description:Comparison of whole genome gene expression profiles of human testis derived ES-like cells with pluripotent stem cells (human embryonic stem cell lines), adult human bone marrow derived mesenchymal stem cells and human dermal fibroblasts. Microarray study with total RNA of three testis derived ES-like cells clusters of one indivual (1) cultured in three different culture conditions A, B,C and embryoid bodies (EB) derived from them at 4, 7, 10, 14 and 18 days of suspension culture. Biological duplicates of human ES cell lines (HUES-1, GFP-hES-3),human bone marrow derived MSC (BMMSC1 and 2) and human dermal fibroblasts (DFB1 and 2) (LONZA CC-2511) at different passages were used as comparison groups.
2011-11-02 | E-GEOD-27203 | biostudies-arrayexpress
Project description:We compared the differential proteins between Mesenchymal stem cells-derived exosomes MRC-5 cell-derived exosomes.
2024-05-21 | PXD033839 | Pride
Project description:Background and aim: Human Induced pluripotent stem (iPS) cells have been derived from dermal fibroblasts, keratinocytes and blood cells by ectopic expression of defined transcription factors.1–5 Application of this approach in human cells would have enormous potential and generate patient-specific pluripotent stem cells to accelerate the implementation of stem cells for clinical treatment of degenerative diseases. In the present study, we investigated whether genetically marked human mesenchymal cells of gut mesentery may give rise to iPS cells. Methods: We used lentiviruses to express Oct4, Sox2, Nanog in mesenchymal cells of gut mesentery, then generated iPS cells were identified in many aspects including morphology, pluripotent markers, global gene expression profile, DNA methylation status at pluripotent cell-specific genes, embryoid bodies and terotomas formation. Results: The resulting iPS cells from mesenchymal cells of gut mesentery were similar to human embryonic stem (ES) cells in morphology, proliferation, surface antigens, gene expression, and epigenetic status of pluripotent cell-specific genes. Furthermore, these cells could differentiate into cell types of the three germ layers in vitro and in teratomas. DNA fingerprinting showed that the human iPS cells were derived from the donor cells and are not a result of contamination. one sample/variable
2009-09-26 | E-GEOD-18180 | biostudies-arrayexpress
Project description:Proteome experiment was peformed on exosomes of human minor salivary gland mesenchymal stem cells and adipose-derived stem cells to find out the same points and difference of these two kinds of exosomes, which can hopefully give further guidance on further therapy research
2024-04-13 | PXD051432 |